Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14301 - 14325 of 15271 in total
Nrx194204 has been used in trials studying the treatment of Parkinson's Disease and Non-small Cell Lung Cancer.
Investigational
Matched Description: … Nrx194204 has been used in trials studying the treatment of Parkinson's Disease and Non-small Cell Lung …
Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and DIABETES MELLITUS, TYPE 2.
Investigational
Matched Description: … Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and
Tirasemtiv has been used in trials studying the treatment of Myasthenia Gravis, Intermittent Claudication, and Amyotrophic Lateral Sclerosis.
Investigational
Matched Description: … Tirasemtiv has been used in trials studying the treatment of Myasthenia Gravis, Intermittent Claudication, and
PAC-14028 has been used in trials studying the treatment of Skin Pruritus, Papulopustular Rosacea, and Erythematotelangiectatic Rosacea.
Investigational
Matched Description: … PAC-14028 has been used in trials studying the treatment of Skin Pruritus, Papulopustular Rosacea, and
Carbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … Carbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor …
Venglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men).
Investigational
Matched Description: … Venglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics …
Ropanicant is under investigation in clinical trial NCT06126497 (Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients).
Investigational
Matched Description: … Ropanicant is under investigation in clinical trial NCT06126497 (Study Evaluating Safety and Efficacy …
CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior to and after transplantation.
Investigational
Matched Description: … to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior to and
Acifluorfen is a protoporphyrinogen oxidase inhibitor.
Experimental
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
Matched Description: … (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and ... XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia. …
Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent. Cirazoline has also been shown to decrease food...
Experimental
Matched Description: … It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. …
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Matched Description: … of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. ... H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment …
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Investigational
Matched Description: … HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and
SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects).
Investigational
Matched Description: … under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability and
Ansofaxine is under investigation in clinical trial NCT02271412 (Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005).
Investigational
Matched Description: … NCT02271412 (Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and
18-methoxycoronaridine is under investigation in clinical trial NCT03084952 (Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients).
Investigational
Matched Description: … investigation in clinical trial NCT03084952 (Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and
ABT-288 is under investigation in clinical trial NCT01018875 (Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease).
Investigational
Matched Description: … ABT-288 is under investigation in clinical trial NCT01018875 (Efficacy and Safety Study of ABT-288 in …
Disaccharide tripeptide glycerol dipalmitoyl is under investigation in clinical trial NCT00003667 (Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma).
Investigational
Matched Description: … glycerol dipalmitoyl is under investigation in clinical trial NCT00003667 (Combination Chemotherapy and
GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).
Investigational
Matched Description: … GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and
Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).
Investigational
Matched Description: … Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD …
IP-2018 is under investigation in clinical trial NCT04686916 (Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients).
Investigational
Matched Description: … IP-2018 is under investigation in clinical trial NCT04686916 (Clinical Trial Studying the Efficacy and
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and ... activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and
Oxaprotiline is a norepinephrine reuptake inhibitor of the tetracyclic antidepressant family that is related to maprotiline. This drug was never marketed. Oxaprotiline is a racemic mixture of the isomers levoprotiline and dextroprotiline. Levoprotiline is the R or levo isomer of oxaprotiline (CGP-12,103-A). Dextroprotiline is the S or dextro isomer of...
Experimental
Matched Description: … Oxaprotiline is a racemic mixture of the isomers levoprotiline and dextroprotiline. ... Both enantiomers have antidepressant effects but levoprotiline also is an antihistamine and dextroprotiline …
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically...
Investigational
Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
Investigational
Matched Description: … a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and
Displaying drugs 14301 - 14325 of 15271 in total